Molbio Diagnostics rises 5% after HDFC Mutual Fund stake purchase
In short
Molbio Diagnostics shares rose more than 5% on October 1. The move followed HDFC Mutual Fund buying a 1.99% stake, and the stock was said to be about 71% above its IPO price.
The rise may support investor interest in the newly listed company, but the reporting does not say the deal size or whether the gain held through the day. Jefferies also gave the stock a Buy rating.
What the reporting says
Molbio Diagnostics shares rose over 5% on October 1 after HDFC Mutual Fund acquired a 1.99% stake in the company through a bulk deal. The stock was also reported to be about 71% above its IPO price, and Jefferies gave it a Buy rating with a ₹1,600 target. The reporting does not state the deal value or whether the buying continued.
Why it matters
Molbio Diagnostics shares moved up over 5% on October 1 after HDFC Mutual Fund bought a 1.99% stake in a bulk deal. The stock was also described as about 71% above its IPO price, and Jefferies set a ₹1,600 target with a Buy rating. This is relevant for investors in the newly listed healthcare name, but the reporting does not state the trade value or broader market reaction.